Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

BST2/Tetherin enhances entry of human cytomegalovirus.

Viswanathan K, Smith MS, Malouli D, Mansouri M, Nelson JA, Früh K.

PLoS Pathog. 2011 Nov;7(11):e1002332. doi: 10.1371/journal.ppat.1002332. Epub 2011 Nov 3.

2.

Ebola Virus Glycoprotein Promotes Enhanced Viral Egress by Preventing Ebola VP40 From Associating With the Host Restriction Factor BST2/Tetherin.

Gustin JK, Bai Y, Moses AV, Douglas JL.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S181-90. doi: 10.1093/infdis/jiv125. Epub 2015 Mar 27.

3.

Molecular mechanism of BST2/tetherin downregulation by K5/MIR2 of Kaposi's sarcoma-associated herpesvirus.

Mansouri M, Viswanathan K, Douglas JL, Hines J, Gustin J, Moses AV, Früh K.

J Virol. 2009 Oct;83(19):9672-81. doi: 10.1128/JVI.00597-09. Epub 2009 Jul 15.

4.

The RING-CH ligase K5 antagonizes restriction of KSHV and HIV-1 particle release by mediating ubiquitin-dependent endosomal degradation of tetherin.

Pardieu C, Vigan R, Wilson SJ, Calvi A, Zang T, Bieniasz P, Kellam P, Towers GJ, Neil SJ.

PLoS Pathog. 2010 Apr 15;6(4):e1000843. doi: 10.1371/journal.ppat.1000843.

5.

Membrane Anchoring by a C-terminal Tryptophan Enables HIV-1 Vpu to Displace Bone Marrow Stromal Antigen 2 (BST2) from Sites of Viral Assembly.

Lewinski MK, Jafari M, Zhang H, Opella SJ, Guatelli J.

J Biol Chem. 2015 Apr 24;290(17):10919-33. doi: 10.1074/jbc.M114.630095. Epub 2015 Mar 10.

6.

BST2/CD317 counteracts human coronavirus 229E productive infection by tethering virions at the cell surface.

Wang SM, Huang KJ, Wang CT.

Virology. 2014 Jan 20;449:287-96. doi: 10.1016/j.virol.2013.11.030. Epub 2013 Dec 15.

7.

Structural basis of HIV-1 Vpu-mediated BST2 antagonism via hijacking of the clathrin adaptor protein complex 1.

Jia X, Weber E, Tokarev A, Lewinski M, Rizk M, Suarez M, Guatelli J, Xiong Y.

Elife. 2014 Apr 29;3:e02362. doi: 10.7554/eLife.02362.

8.

Activities of transmitted/founder and chronic clade B HIV-1 Vpu and a C-terminal polymorphism specifically affecting virion release.

Jafari M, Guatelli J, Lewinski MK.

J Virol. 2014 May;88(9):5062-78. doi: 10.1128/JVI.03472-13. Epub 2014 Feb 26.

9.

Antiviral inhibition of enveloped virus release by tetherin/BST-2: action and counteraction.

Le Tortorec A, Willey S, Neil SJ.

Viruses. 2011 May;3(5):520-40. doi: 10.3390/v3050520. Epub 2011 May 6. Review.

10.

Tetherin restricts direct cell-to-cell infection of HIV-1.

Kuhl BD, Sloan RD, Donahue DA, Bar-Magen T, Liang C, Wainberg MA.

Retrovirology. 2010 Dec 24;7:115. doi: 10.1186/1742-4690-7-115.

11.

Requirements within the Ebola Viral Glycoprotein for Tetherin Antagonism.

Vande Burgt NH, Kaletsky RL, Bates P.

Viruses. 2015 Oct 26;7(10):5587-602. doi: 10.3390/v7102888.

12.

Role of the endosomal ESCRT machinery in HIV-1 Vpu-induced down-regulation of BST2/tetherin.

Janvier K, Roy N, Berlioz-Torrent C.

Curr HIV Res. 2012 Jun;10(4):315-20. Review.

PMID:
22524180
13.

The Interferon-Inducible Protein Tetherin Inhibits Hepatitis B Virus Virion Secretion.

Yan R, Zhao X, Cai D, Liu Y, Block TM, Guo JT, Guo H.

J Virol. 2015 Sep;89(18):9200-12. doi: 10.1128/JVI.00933-15. Epub 2015 Jun 24.

14.

The Ebola virus glycoprotein and HIV-1 Vpu employ different strategies to counteract the antiviral factor tetherin.

Kühl A, Banning C, Marzi A, Votteler J, Steffen I, Bertram S, Glowacka I, Konrad A, Stürzl M, Guo JT, Schubert U, Feldmann H, Behrens G, Schindler M, Pöhlmann S.

J Infect Dis. 2011 Nov;204 Suppl 3:S850-60. doi: 10.1093/infdis/jir378.

15.

Stimulation of NF-κB activity by the HIV restriction factor BST2.

Tokarev A, Suarez M, Kwan W, Fitzpatrick K, Singh R, Guatelli J.

J Virol. 2013 Feb;87(4):2046-57. doi: 10.1128/JVI.02272-12. Epub 2012 Dec 5.

16.

BST2/tetherin inhibits dengue virus release from human hepatoma cells.

Pan XB, Han JC, Cong X, Wei L.

PLoS One. 2012;7(12):e51033. doi: 10.1371/journal.pone.0051033. Epub 2012 Dec 7.

17.

Differential Control of BST2 Restriction and Plasmacytoid Dendritic Cell Antiviral Response by Antagonists Encoded by HIV-1 Group M and O Strains.

Bego MG, Cong L, Mack K, Kirchhoff F, Cohen ÉA.

J Virol. 2016 Oct 28;90(22):10236-10246. Print 2016 Nov 15.

18.

Rab7A is required for efficient production of infectious HIV-1.

Caillet M, Janvier K, Pelchen-Matthews A, Delcroix-Genête D, Camus G, Marsh M, Berlioz-Torrent C.

PLoS Pathog. 2011 Nov;7(11):e1002347. doi: 10.1371/journal.ppat.1002347. Epub 2011 Nov 3.

19.

BST2/tetherin inhibition of alphavirus exit.

Ooi YS, Dubé M, Kielian M.

Viruses. 2015 Apr 22;7(4):2147-67. doi: 10.3390/v7042147.

20.

Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2.

Jia B, Serra-Moreno R, Neidermyer W, Rahmberg A, Mackey J, Fofana IB, Johnson WE, Westmoreland S, Evans DT.

PLoS Pathog. 2009 May;5(5):e1000429. doi: 10.1371/journal.ppat.1000429. Epub 2009 May 15.

Supplemental Content

Support Center